Core Viewpoint - The shareholder Shanghai Zhangjiang Biopharmaceutical Base Development Co., Ltd. plans to reduce its stake in Yinuo through a concentrated bidding process, indicating a strategic move for operational development needs [1] Shareholder Information - Shanghai Zhangjiang Biopharmaceutical Base Development Co., Ltd. holds 11.02 million shares, representing 7.82% of the total shares [1] - The planned reduction involves selling up to 1.4098 million shares, which accounts for 1.00% of the total shares [1] Reduction Timeline - The reduction period is set from December 22, 2025, to March 20, 2026 [1] - The selling price will be determined based on market conditions [1] Regulatory Compliance - The shareholder is allowed to reduce no more than 1.00% of the total shares within any continuous 90-day period [1]
益诺思：股东张江生物医药拟减持不超过1%